Hepatocellular Carcinoma-Cause, Treatment and Metastasis

Tang, Zhao–You

doi:10.3748/wjg.v7.i4.445

Cited by 341 publications

(227 citation statements)

References 188 publications

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…23 Therefore, we conclude that systemic delivery of Asor-Apoptin is a greatly improved step toward clinical treatment of HCC, for only a small percentage of primary and secondary liver tumors are suitable for surgical resection, whereas systemic chemotherapy has been disappointing in the past. [24][25][26] Systemic gene delivery with Apoptin offers unique advantages over current approaches for hepatocarcinoma therapy. Resistance to hepatocarcinoma therapies is often caused by the inactivation of apoptotic pathways.…”

Section: Asor-apoptinmentioning

confidence: 99%

Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor

Sun

et al. 2006

Cancer Gene Ther

View full text Add to dashboard Cite

Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a systemic delivery vehicle containing the Apoptin gene linked to asialoglycoprotein (Asor), which targets asialoglycoprotein receptor (ASGPR) present only on the surface of hepatocytes. In vitro, the protein-DNA complex Asor-Apoptin induced apoptosis in HepG2 hepatocarcinoma cells but not in normal L-02 hepatocytes. Non-hepatocyte-derived tumorigenic human A549 cells lacking the membrane ASGPR were not affected by Asor-Apoptin. In vivo systemic delivery of Asor-Apoptin via the tail vein into mice bearing in situ hepatocarcinoma resulted in specific and efficient distribution of Apoptin in both hepatocarcinoma cells and normal hepatocytes. Five days after injection of Asor-Apoptin, the in situ hepatocarcinomas showed significant signs of regression, whereas the surrounding normal hepatocytes did not. Systemically delivered Asor-LacZ expressing non-apoptotic LacZ gene did not inhibit tumor growth. Our data reveal that systemic delivery of Asor-Apoptin specifically induces apoptosis in malignant hepatocytes and thus constitutes a powerful and safe therapeutics against hepatocarcinomas.

show abstract

Section: Asor-apoptinmentioning

confidence: 99%

Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor

Sun

et al. 2006

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…HBV and HCV infections have each been shown to markedly increase the risk of developing HCC. In China, HBV has, for several decades, been the major cause of liver disease (Tang, 2001). Soon after the identification of HCV and the development of testing HCV infection, it has become increasingly evident that chronic HCV infection also plays an important role in chronic hepatic disease including HCC (Yano et al, 1993;Tsai et al, 1994).…”

mentioning

confidence: 99%

A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China

et al. 2005

View full text Add to dashboard Cite

We investigated whether concurrent infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) in China, a hyperepidemic area for these infections, was associated with a higher risk of causing hepatocellular carcinoma (HCC) than each infection alone in a metaanalysis in China, 32 case -control studies involving 3201 cases and 4005 controls, identified from a computer-based literature search from 1966 to 2004. The pooled odds ratio and 95% confidence interval (CI) for HBsAg positivity was 14.1 (95% CI: 10.6 -18.8); for anti-HCV/HCV RNA positivity was 4.6 (95% CI: 3.6 -5.9); for HBsAg positivity and anti-HCV/HCV RNA negativity were 15.6 (95% CI: 11.5 -21.3); for HBsAg negativity and anti-HCV/HCV RNA positivity were 8.1 (95% CI: 5.0 -13.0); and positivity for both HBsAg and anti-HCV/HCV RNA was 35.7 (95% CI: 26.2 -48.5). We conclude that HBV and HCV infections are important independent risk factors for HCC in China, and that dual infection by HBV and HCV is associated with a higher risk of causing HCC than each infection alone, suggesting a synergism between HBV and HCV. ). More than 500 000 new cases are currently diagnosed yearly, with an ageadjusted worldwide incidence of 5.5 -14.9 per 100 000 population (Llovet et al, 2003). About 110 000 persons die each year from HCC in China, which accounts for 45% of the deaths from HCC worldwide. China is also a hyperepidemic area for hepatitis B virus (HBV) infection (with an estimated carrier rate exceeding 10% in the general population) and hepatitis C virus (HCV) infection (with a prevalence of anti-HCV 3.1% of in the general population) (Xuezhong et al, 1999). HBV and HCV infections have each been shown to markedly increase the risk of developing HCC. In China, HBV has, for several decades, been the major cause of liver disease (Tang, 2001). Soon after the identification of HCV and the development of testing HCV infection, it has become increasingly evident that chronic HCV infection also plays an important role in chronic hepatic disease including HCC (Yano et al, 1993;Tsai et al, 1994). There have been several meta-analyses of the relation of HBV and HCV infections to HCC in China, but the relation of dual infection to HCC has not received similar attention. In fact, this is not rare in HCC patients and a higher morbidity in HCC patients with dual infection has been reported than in those with one infection (Benvegnu et al, 1994). The main difficulty in evaluating the relationship of dual infection to HCC is the rarity of concurrent infection in subjects without clinically evident liver disease. Only large case -control studies that include people unaffected by chronic liver diseases as controls can allow the interaction to be properly assessed. The aim of this meta-analysis is to assess the interaction between HBV and HCV infections among 32 casecontrol studies of HCC. MATERIALS AND METHODS Data sourcesWe searched the published Chinese literature from 1979 to February 2004 and Medline database from 1966 to February 2004 to identify case -control studies of the...

show abstract

“…All tumor-bearing mice were divided randomly into groups (6 mice/group). The treatments were initiated on day 4 when tumor volume reached about 40-50 mm 3 (designated as day 0) and were performed once every two days for two weeks. The drugs were injected into mice subcutanesly (s.c.).…”

Section: In Vivo Animal Tumor Model Experimentsmentioning

confidence: 99%

“…Despite many advances have been made in the clinical study of HCC and the achievement of long-term survival of patients in some clinical centers, only a definitive subset of cases is cured by surgery, and the overall dismal outcome of patients with HCC has not changed (3). Hence, exploration of more effective and safer therapeutic modalities is needed.…”

Section: Introductionmentioning

confidence: 99%

Combination of Human Fas (CD95/Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response

Liu

Qiu

et al. 2009

Cell Mol Immunol

View full text Add to dashboard Cite

Hepatocellular Carcinoma-Cause, Treatment and Metastasis

Cited by 341 publications

References 188 publications

Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor

Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor

A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China

Combination of Human Fas (CD95/Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response

Contact Info

Product

Resources

About